Recently, clinical trials with DLBCL patients have explored the prognostic effect and interdependence of the cell-of-origin (COO) classification and Hans algorithm, dual expression of MYC and BCL-2 proteins, and MYC, BCL-2, and BCL-6 translocations (4) using complementary DNA microarrays and immunohistochemical staining with various markers, including a cluster of differentiation (CD)10, BCL-6, and multiple myeloma-1/interferon regulatory factor-4 (MUM-1). This evidence concerns the gene MYC and diffuse large B-cell lymphoma.